Evidence map›Paper›PMID 42712082›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial.

Ruth Ottman, John B Wetmore, Cheng-Shiun Leu, Wendy R Uhlmann, Jill Goldman, Sophia Rodriguez, Daniela Diaz Caro, María Cabán, Sarah McCain, Drew Blasco and 5 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04471779 (The IDEAL Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04471779 nacompletednot on this map

The IDEAL Study: Information About Alzheimer's Disease for Latinos in New York City

TypeinterventionalSponsorColumbia UniversityRan2021 to 2025Enrolled374ConditionsAlzheimer DiseaseArmsDisclosure of APOE genotype
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruth OttmanGertrude H. Sergievsky Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.ORCID https://orcid.org/0000-0001-7074-242X
John B WetmoreGertrude H. Sergievsky Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
Cheng-Shiun LeuDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA.
Wendy R UhlmannDivision of Genetic Medicine, Department of Internal Medicine and Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
Jill GoldmanDepartment of Neurology, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
Sophia RodriguezGertrude H. Sergievsky Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
Daniela Diaz CaroGertrude H. Sergievsky Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
María CabánDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.
Sarah McCainDepartment of Health Behavior and Health Equity, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Drew BlascoDepartment of Social and Behavioral Health, School of Public Health, University of Nevada, Las Vegas, Nevada, USA.
Rafael A LantiguaDepartment of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
Ana Abraido-LanzaColumbia School of Social Work, New York, New York, USA.
Wendy K ChungBoston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
J Scott RobertsDepartment of Health Behavior and Health Equity, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Karolynn SiegelDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
VASCULAR FACTORS AND MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASEP01AG007232 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DEVANAND, DAVANGERE P · 1989 to 2008
$21.7M
Impacts of receiving Alzheimer's disease genetic risk information among Latinos in northern ManhattanR01AG062528 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI OTTMAN, RUTH, SIEGEL, KAROLYNN · 2020 to 2024
$14.8M
Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)R01AG072474 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, MANLY, JENNIFER JAIE · 2021 to 2025
$13.3M
Epidemiology of Biomarkers of Risk and Progression in LOADR01AG037212 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P, SCHUPF, NICOLE · 2010 to 2015
$10.1M
Genetic Epidemiology of Cerebrovascular Factors in Alzheimer's DiseaseRF1AG054023 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P · 2016 to 2018
$8.9M
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1TR001873NIA NIH HHS P01 AG007232NIA NIH HHS R01 AG037212NIA NIH HHS R01 AG062528NIA NIH HHS R01AG062528NIA NIH HHS R01 AG072474NIA NIH HHS RF1 AG054023
6 · The paper itself

Abstract

introductionLatinos face increased Alzheimer's disease (AD) risk but are underrepresented in studies of APOE genotype disclosure. We evaluated the psychological impacts of APOE disclosure in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) study, a randomized controlled trial among Latinos in New York City.

methodsLatino northern Manhattan residents without self-reported AD (mean age 52, 69% women, 49% college graduates) were randomized in the period August 2021 to July 2024 to receive AD risk estimates to age 85 incorporating APOE genotype, family history, and ethnicity (disclosure) or the same factors excluding APOE (non-disclosure). Bilingual genetic counselors delivered risk estimates to both groups, unmasked to randomization. Follow-up surveys were completed 6 weeks, 9 months, and 15 months after risk delivery. Primary outcomes were impact of genetic testing in AD (IGT-AD) and Impact of Event Scale-Revised (IES-R). Secondary outcomes were changes from baseline in depression, anxiety, and perceived AD threat. Analyses used intention-to-treat with multiple imputation.

resultsDisclosure (N = 194) and non-disclosure (N = 180) groups did not differ on IGT-AD (mean disclosure-non-disclosure difference [MD] at 6 weeks: -1.5, p = 0.14; 9 months: -1.2, p = 0.35; 15 months: -2.0, p = 0.07), IES-R (MD at 6 weeks: 0.00, p = 0.98; 9 months: 0.01, p = 0.84; 15 months: 0.03, p = 0.64), or change in secondary outcomes. Occurrence of disclosure-related adverse events was similar in the disclosure (N = 2) and non-disclosure (N = 3) groups. DISCUSSION: In this Latino cohort, APOE disclosure did not have clinically significant adverse psychological effects, addressing an important evidence gap.

trial registrationClinicalTrials.gov NCT04471779.

Indexed as

Alzheimer DiseaseApolipoproteins EDisclosureHispanic or LatinoAgedAged, 80 and overFemaleGenetic TestingGenotypeHumansMaleMiddle AgedNew York CityApolipoproteins EAlzheimer's diseaseAPOEethicalgenetic testingHispanicLatinolegalpsychologypsychosocialsocial implications

Identifiers

PMID42712082
PMCPMC13554978

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.